Hyperthermia as an adjunctive treatment for soft-tissue sarcoma

References

• Hildebrandt B, Wust P. The biologic rationale of hyperthermia. Cancer Treat. Res.134, 171–184 (2007).
   PubMedGoogle Scholar
• Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol.43, 33–56 (2002).
   PubMed Web of Science ®Google Scholar
• Issels RF. Hyperthermia adds to chemotherapy. Eur. J. Cancer44(17), 2546–2554 (2008).
   PubMed Web of Science ®Google Scholar
• Bauer KD, Henle KJ. Arrhenius analysis of heat survival curves from normal and thermotolerant CHO cells. Radiat. Res.78, 251–263 (1979).
   PubMed Web of Science ®Google Scholar
• Streffer C. Biological basis of thermotherapy (with special reference to oncology). In: Biological Basis of Oncologic Thermotherapy. Gautherie M (Ed.). Springer, Berlin, Germany 1–72 (1990).
   Google Scholar
• Dewey WC, Thrall D, Gilette EL. Hyperhermia and radiation – a selective thermal effect on chronically hypoxic tumor cells in vivo. Int. J. Radiat. Oncol. Biol. Phys.2, 99–103 (1977).
   PubMed Web of Science ®Google Scholar
• Westra A, Dewey WC. Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.19(5), 467–477 (1971).
   PubMed Web of Science ®Google Scholar
• Gerner EW. Definition of thermal dose. In: Hyperthermic Oncology. Overgaard J (Ed.). Taylor and Francis, London, UK 253–262 (1985).
   Google Scholar
• Overgaard J, Suit HD. Time–temperature relationship in hyperthermic treatment of malignant and normal tissue in vivo. Cancer Res.39(8), 3248–3253 (1979).
   PubMed Web of Science ®Google Scholar
• Sapareto SA. Thermal isoeffect dose, addressing the problem of thermotolerance. Int. J. Hyperthermia3(4), 297–305 (1987).
   PubMed Web of Science ®Google Scholar
• Urano M. Kinetics of thermotolerance in normal and tumor tissues: a review. Cancer Res.46, 474–482 (1986).
   PubMed Web of Science ®Google Scholar
• Jung H. A generalized concept of cell killing by heat. Radiat. Res.116(1), 56–72 (1988).
   PubMed Web of Science ®Google Scholar
• Li GC, Mivechi NF, Weitzel G. Heat shock proteins, thermotolerance, and their relevance for clinical hyperthermia. Int. J. Hyperthermia11(4), 459–488 (1995).
   PubMed Web of Science ®Google Scholar
• Song CW, Lyons JC, Griffin RJ, Makepeace CM, Cragoe EJ. Increase of thermosensibility of tumor cells by lowering intracellular pH. Cancer Res.53, 1599–1601 (1993).
   PubMed Web of Science ®Google Scholar
• Reinhold HS, Endrich B. Tumor microcirculation as a target for hyperthermia. Int. J. Hyperthermia2, 111–137 (1986).
   PubMedGoogle Scholar
• Vaupel PW, Kelleher DK. Metabolic status and reaction to heat of normal and tumor tissue. In: Thermotherapy and Thermochemotherapy Volume 1. Seegenschmiedt MH, Fessenden P, Vernon CC (Eds). Springer Verlag, Berlin, Germany 157–176 (1995).
   Google Scholar
• Raaphorst GP. Fundamental aspects of hyperthermic biology. In: An Introduction to the Practical Aspects of Clinical Hyperthermia. Field SB, Hand JW (Eds). Taylor and Francis, London, UK 10–54 (1990).
   Google Scholar
• Song CWM, Shakil A, Griffin RJ, Okajima K. Improvement of tumor oxygenation status by mild temperature hyperthermia alone or in combination with carbogen. Semin. Oncol.24, 626–632 (1997).
   PubMed Web of Science ®Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization, mode of action and clinical relevance. Int. J. Radiat. Biol.77, 399–408 (2001).
   PubMed Web of Science ®Google Scholar
• Stewart FA, Denekamp J. The therapeutic advantage of combined heat and x-rays on a mouse fibrosarcoma. Br. J. Radiol.51(604), 307–316 (1978).
   PubMed Web of Science ®Google Scholar
• Marino C, Cividalli A. Combined radiation and hyperthermia: effects of the number of heat fractions and their interval on normal and tumour tissues. Int. J. Hyperthermia8, 771–781 (1992).
   PubMed Web of Science ®Google Scholar
• Song CV. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res.44(Suppl.), S4721–S4730 (1984).
   PubMed Web of Science ®Google Scholar
• Dahl O. Interaction of heat and drugs in vitro and in vivo. In: Thermoradiotherapy and Thermochemotherapy Volume 1. Seegenschmiedt MH, Fessenden P, Vernon CC (Eds). Springer Verlag, Berlin, Germany 103–121 (1995).
   Google Scholar
• Wust P, Hildebrandt B, Sreenivasa G et al. Hyperthermia in combined treatment of cancer. Lancet Oncol.3, 487–497 (2002).
   PubMed Web of Science ®Google Scholar
• Honess DJ, Donaldson J, Workman P, Bleehen NM. The effect of systemic hyperthermia on melphalan pharmocokinetics in mice. Br. J. Cancer51, 77–84 (1985).
   PubMed Web of Science ®Google Scholar
• Li GC, He F, Shao X et al. Adenovirus mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res.63(12), 3268–3274 (2003).
   PubMed Web of Science ®Google Scholar
• Bull JCM. Clinical practice of whole-body hyperthermia: new directions. In: Thermoradiotherapy and Thermochemotherapy Volume 2. Seegenschmiedt MH, Fessenden P, Vernon CC (Eds). Springer Verlag, Berlin, Germany 303–322 (1996).
   Google Scholar
• Robins HI; on behalf of SHOWG members. Meeting report. Systemic hyperthermia oncological working group. Oncology52, 260–263 (1995).
   PubMed Web of Science ®Google Scholar
• Robins HI, Dennis WH, Neville AJ et al. A nontoxic system for 41.8°C whole-body hyperthermia: results of a Phase I study using a radiant heat device. Cancer Res.45, 3937–3944 (1985).
   PubMed Web of Science ®Google Scholar
• Hetzel FW, Mattiello J. Interactions of hyperthermia with other modalities. In: Medical Physics Monograph Number 16. Biological, Physical and Clinical aspects of Hyperthermia. Paliwal BR, Hetzel FW, Dewhirst MW (Eds). American Institute of Physics, MD, USA 30–56 (1987).
   Google Scholar
• Grobmyer SR, Make RG, Demetri GD et al. Neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol.15, 1667–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Spiro IJ, Suit H, Gebhardt M et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas. Proc. Am. Soc. Clin. Oncol.15, 524 (1996) (Abstract 168).
   Google Scholar
• Kraybill WG, Harris J, Spiro IJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas on the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J. Clin. Oncol.24, 619–625 (2006).
   PubMed Web of Science ®Google Scholar
• Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neoadjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur. J. Cancer37, 1096–1103 (2001).
   PubMed Web of Science ®Google Scholar
• Issels RD, Prenninger SW, Nagele A et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a Phase II study. J. Clin. Oncol.8, 1818–1829 (1991).
   Web of Science ®Google Scholar
• Issels RD, Mittermueller J, Gerl A et al. Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: updated report on 65 patients. J. Cancer Res. Clin. Oncol.117(Suppl. 4), 141–147 (1991).
   PubMed Web of Science ®Google Scholar
• Issels RD, Abdel-Rahman S, Wendtner CM et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk soft tissue sarcomas (HR-STS) of adults: long-term results of a Phase II study. Eur. J. Cancer37, 1599–1608 (2001).
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Abdel-Rahman S, Baumert J et al. Treatment of primary, recurrent or inadequately resected high-risk soft tissue sarcomas (HR-STS) of adults: results of a Phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur. J. Cancer,37, 1609–1616 (2001).
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Abdel-Rahman S, Krych M et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J. Clin. Oncol.20, 3156–3164 (2002).
   PubMed Web of Science ®Google Scholar
• Issels RD, Lindner LH, Wust P et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcoma (STS) of the extremities, the body wall and the abdomen: a Phase III randomised prospective trial (EORTC/ESHO Intergroup Trial). Proc. Am. Soc. Clin. Oncol.25(Suppl. 18), S547 (2007).
   Google Scholar
• Stotter AT, A’Hern RP, Fisher C, Mott AF, Fallowfield ME, Westbury G. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival. Cancer65, 1119–1129 (1990).
   PubMed Web of Science ®Google Scholar
• Gustafson P, Rööser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer67(8), 2083–2086 (1991).
   PubMed Web of Science ®Google Scholar
• Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low dose tumor necrosis factor-α and melphalan in hyperthermic isolated limb perfusion. Br. J. Surg.80, 995–997 (1993).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt Koops H, Liénard D et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J. Clin. Oncol.14, 2653–2665 (1996).
   PubMed Web of Science ®Google Scholar
• Santinami M, Deraco M, Azzarelli A et al. Treatment of recurrent sarcoma of the extremities by isolated perfusion using tumor necrosis factor-α and melphalan. Tumori82, 579–584 (1996).
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg.224, 756–765 (1996).
   PubMed Web of Science ®Google Scholar
• Gutman M, Inbar M, Lev-Shlush D et al. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer79, 1129–1137 (1997).
   PubMed Web of Science ®Google Scholar
• Eggermont AM Schraffordt Koops H, Klausner JM et al. Limb salvage by isolation limb perfusion with tumor necrosis factor-α and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc. Am. Soc. Clin. Oncol.11, 497 (1999).
   Google Scholar
• Rossi CR, Foletto M, Di Filippo F et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer86, 1742–1749 (1999).
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Pujol N, Liénard D. Limb salvage by neoadjuvant isolated perfusion with TNF-α and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur. J. Surg. Oncol.26, 669–678 (2000).
   PubMed Web of Science ®Google Scholar
• Hohenberger P, Kettelhack C, Hermann A, Schlag PM. Functional outcome after preoperative isolated limb perfusion with rhTNF-α/melphalan for high-grade extremity sarcoma. Eur. J. Cancer37, S34–S35 (2001).
   Google Scholar
• Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-α and melphalan for unresectable soft tissue sarcoma of the extremities. Cancer98, 1483–1490 (2003).
   PubMed Web of Science ®Google Scholar
• Grünhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM. TNF dose reduction in isolated limb perfusion. Eur. J. Surg. Oncol.31, 1011–1019 (2005).
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Laplanche A, Lejeune F et al. Limb salvage with isolated perfusion for soft tissue sarcoma, could less TNF-α be better? Ann. Oncol.16, 1061–1068 (2005).
   PubMed Web of Science ®Google Scholar
• Rossi CR, Mocellin S, Pilati P et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor-α and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann. Surg. Oncol.12, 398–405 (2005).
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-α and melphalan for limb-threatening soft tissue sarcoma. Cancer106, 1776–1784 (2006).
   PubMed Web of Science ®Google Scholar
• Pennacchioli E, Deraco M, Mariani L et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann. Surg. Oncol.14(2), 553–559 (2007).
   PubMed Web of Science ®Google Scholar
• van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ. Isolated limb perfusion with tumor necrosis factor-α and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann. Surg. Oncol.14(4), 1499–1506 (2007).
   PubMed Web of Science ®Google Scholar
• Bedard V, Vataire C, Desouche C et al. A prospective database of 100 patients with locally soft tissue sarcoma (STS) treated by isolated limb perfusion with melphalan and TNFα 1 mg. J. Clin. Oncol. Proc.25(Suppl. 18), 10010 (2007).
   Google Scholar
• Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with Melphalan and tumor necrosis factor a for advanced melanoma and soft tissue sarcoma. Ann. Surg. Oncol.14(1), 230–238 (2007).
   PubMed Web of Science ®Google Scholar
• Verhoef C, de Wilt JH, Grunhagen DJ, van Geel AN, ten Hagne TL, Eggermont AM. Isolated limb perfusion with melphalan and TNF-α in the treatment of extremity sarcoma. Curr. Treat. Options Oncol.8(6), 417–427 (2007).
   PubMedGoogle Scholar
• Bilimoria MM, Holtz DJ, Mirza NQ et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer94(9), 2441–2446 (2002).
   PubMed Web of Science ®Google Scholar
• Vernick JJ, Oates GD, Magell J, Fried C. The use of anticancer agents for control of tumor growth in the peritoneal cavity after seeding with an experimental tumor. J. Surg. Res.4, 559–561 (1964).
   PubMedGoogle Scholar
• Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res.40(2), 256–260 (1980).
   PubMed Web of Science ®Google Scholar
• Mavligit GM, Zukiwski AA, Salem PA et al. Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer68(2), 321–323 (1991).
   PubMed Web of Science ®Google Scholar
• Dietel M, Arps H, Gerding D et al. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin. J. Cancer Res. Clin. Oncol.114(2), 197–203 (1988).
   PubMed Web of Science ®Google Scholar
• Wiedemann G, Mella O, Roszinski S et al. Hyperthermia enhances mitoxantrone cytotoxicity on human breast carcinoma and sarcoma xenografts in nude mice. Int. J. Radiat. Oncol. Biol. Phys.24(4), 669–673 (1992).
   PubMed Web of Science ®Google Scholar
• Lim SJ, Cormier JN, Feig BW et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann. Surg. Oncol.14(8), 2309–2318 (2007).
   PubMed Web of Science ®Google Scholar
• Bonvalot S, Cavalcanti A, Le Pechoux C et al. Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. Eur. J. Surg. Oncol.31(8), 917–923 (2005).
   PubMed Web of Science ®Google Scholar
• Rossi CR, Casali P, Kusamura S, Baratti D, Deraco M. The consensus statement on the locoregional treatment of abdominal sarcomatosis. J. Surg. Oncol.98(4), 291–294 (2008).
   PubMed Web of Science ®Google Scholar
• Horseman MR. Angiogenesis and vascular targeting: relevance for hyperthermia. Int. J. Hyperthermia24(1), 57–65 (2008).
   PubMed Web of Science ®Google Scholar
• Lindner LH, Schlemmer M, Hohenberger P et al. First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)22(Suppl. 14), 9015 (2004)
   Google Scholar